Search

Displaying results 1181 - 1190 of 8468 in total
  1. Drug

    Flumethasone

    go.drugbank.com/drugs/DB00663
    ApprovedVet approved

    As it is a privalate salt, its anti-inflammatory action is concentrated at the site of application.

    Mixtures: PMS-flumethasone-clioquinol
  2. Drug

    Phenelzine

    go.drugbank.com/drugs/DB00780
    ApprovedInvestigational

    [A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.

  3. Drug

    Oxymetholone

    go.drugbank.com/drugs/DB06412
    ApprovedIllicit

    Anabolic-androgenic steroids (AAS), such as oxymetholone, have been abused by bodybuilders and athletes. … In 2009, no producers of oxymetholone were identified worldwide (SRI 2009), but it was available from 14 suppliers, including 8 U.S. suppliers (ChemSources 2009).

  4. Drug

    Gamolenic acid

    go.drugbank.com/drugs/DB13854
    ApprovedWithdrawn

    Gamolenic acid is produced minimally in the body as the delta 6-desaturase metabolite of [DB00132]. It is converted to [DB00154], a biosynthetic precursor of monoenoic prostaglandins such as PGE1. … It is an omega-6 polyunsaturated fatty acid (PUFA) also referred to as 18:3n-6; 6,9,12-octadecatrienoic acid; and cis-6, cis-9, cis-12- octadecatrienoic acid [F27].

  5. Drug

    Nusinersen

    go.drugbank.com/drugs/DB13161
    ApprovedInvestigational

    FDA in December, 2016 as Spinraza for the treatment of children and adults with spinal muscular atrophy (SMA). It is adminstrated as direct intrathecal injection. … An antisense oligonucleotide that induces survival motor neuron (SMN) protein expression, it was approved by the U.S.

  6. Drug

    GS030-DP

    go.drugbank.com/drugs/DB17847
    Investigational

    It targets retinal ganglion cells that encodes a light-sensitive channelrhodopsin, ChrimsonR-tdTomato (ChR-tdT), delivered by an AAV2.7m8 vector.

  7. Drug

    Lumateperone

    go.drugbank.com/drugs/DB06077
    ApprovedInvestigational

    [A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity. … [A189093] It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology

  8. Drug

    Protein S human

    go.drugbank.com/drugs/DB13149
    ApprovedInvestigational

    Protein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties [A19561]. It serves as a negative feedback mechanism in the coagulation cascade.

  9. Drug

    Medrogestone

    go.drugbank.com/drugs/DB09124
    ApprovedWithdrawn

    [L1118] It was never approved by the FDA. … It was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.

  10. Drug

    Carisoprodol

    go.drugbank.com/drugs/DB00395
    Approved

    In January 2012, this drug was classified as a Schedule IV substance under the controlled substances act in several US states due to alarming rates of abuse [A176062, A176077] despite having a low potential